yahoo_financeOriginal article
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
Phase 3positivePositive
AI Analysis
Summary
MoonLake Immunotherapeutics reported narrowed Q2 losses and positive Phase 3 trial results in psoriatic arthritis, meeting clinical endpoints.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 PsA trial met clinical goals
Importance:7/10
Sentiment:
0.70
Phase 3PsAImmunotherapyClinical TrialQ2 Earnings
Related Companies
Read the original article
Published by yahoo_finance on August 10, 2026 1:08 PM